Our community narratives are driven by numbers and valuation.
Following a landmark earnings report, a new "800-pound gorilla" has been uncaged. We analyze the three-part moat that has de-risked IonQ’s "100-Bagger" thesis.Read more
Alphabet’s Q3 2024 results reveal an impressive 15% revenue growth to $88.3 billion, driven by robust ad revenue and a 35% surge in Google Cloud. With strong gains across Search, YouTube, and AI-powered enterprise solutions, Alphabet remains a leader in digital advertising and next-gen tech, pushing margins higher amidst fierce competition.Read more
Earnings Show Exceptional Profitability Interactive Brokers (NASDAQ: IBKR) reported another standout quarter, reinforcing its position as one of the most operationally efficient brokerages in global finance. For Q3 2025, the company posted GAAP net revenues of $1.655 billion, up from $1.365 billion in the same quarter last year.Read more
1. The Foundry King: The Core of Modern Tech TSMC invented the dedicated foundry model in 1987 and today commands ~50% global market share, manufacturing chips for clients like Apple, Nvidia, AMD, Qualcomm, and others.Read more

Catalysts Sprouts Farmers Market's transformation under CEO Jack Sinclair is delivering exceptional results. The company generated $4.46B in revenue during H1 2025 (+18% YoY) while expanding gross margins to 39.2% from 38.1%—a remarkable achievement in the razor-thin grocery industry.Read more

1. The Empire of E-Commerce + Everything Else Amazon is the unchallenged king of U.S. e-commerce , with over 37% market share — Walmart is still staring at the rearview mirror.Read more

Company Overview Founded in 2003 by Peter Thiel, Alex Karp, Stephen Cohen, Joe Lonsdale, and Nathan Gettings, Palantir Technologies emerged from the shared vision of transforming how data could be used to solve complex problems. Peter Thiel, a co-founder of PayPal and a prominent venture capitalist, brought his knack for identifying transformative opportunities.Read more

The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.Read more
Once again, I boldly foretell a future possibility for the years ahead. Some reading this may scoff, or may laugh and move on.Read more
